CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 19,192 enrolled
Drug / intervention
Alogliptindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01964963
NCT01964963N/ACompleted
CompareCT.gov

Alogliptin (Nesina) Tablets Special Drug Use Surveillance: Mild Type 2 Diabetes Mellitus

Takeda·observational·Posted Oct 17, 2013·Updated Nov 21, 2019

In Brief

An observational study evaluating Alogliptin for Type 2 Diabetes Mellitus. Completed, enrolled 19,192 participants across 1 site.

Detailed Summary

The purpose of this study is to examine the safety and efficacy of long-term treatment with alogliptin (Nesina) in patients with mild type 2 diabetes mellitus in the routine clinical setting.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesJapan
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 17, 2013
Enrollment StartAug 3, 2011
Primary CompletionJul 31, 2017
TodayJul 2, 2026
Enrollment to primary: 6.0 yearsPosted 12.7 years ago

Interventions

Alogliptindrug

Alogliptin tablets